Department of Medicine
David M. Nanus has not added Biography.
If you are David M. Nanus and would like to personalize this page please email our Author Liaison for assistance.
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN.
Cancer cell Jan, 2004 | Pubmed ID: 14749127
Aminopeptidase A is a functional target in angiogenic blood vessels.
Cancer cell Feb, 2004 | Pubmed ID: 14998491
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.
Cancer Jan, 2002 | Pubmed ID: 11815966
Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens.
Cancer research Mar, 2002 | Pubmed ID: 11912136
Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2002 | Pubmed ID: 12114445
Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?
Cancer investigation , 2002 | Pubmed ID: 12197243
The utility of monoclonal antibodies in the imaging of prostate cancer.
Seminars in urologic oncology Aug, 2002 | Pubmed ID: 12215974
Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.
Cancer Sep, 2002 | Pubmed ID: 12216088
High expression of the Met receptor in prostate cancer metastasis to bone.
Urology Dec, 2002 | Pubmed ID: 12475693
Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase.
Anticancer research Sep-Oct, 2002 | Pubmed ID: 12529960
Chemotherapeutic strategies for renal cell carcinoma.
The Urologic clinics of North America Aug, 2003 | Pubmed ID: 12953758
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
The Journal of urology Nov, 2003 | Pubmed ID: 14532761
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Seminars in oncology Oct, 2003 | Pubmed ID: 14571414
Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2003 | Pubmed ID: 14581364
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.
The Journal of urology Dec, 2003 | Pubmed ID: 14610403
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
The Journal of urology Dec, 2003 | Pubmed ID: 14610416
Of peptides and peptidases: the role of cell surface peptidases in cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2003 | Pubmed ID: 14695128
Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins.
The Journal of biological chemistry Mar, 2004 | Pubmed ID: 14704146
Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase.
Clinical cancer research : an official journal of the American Association for Cancer Research Jan, 2004 | Pubmed ID: 14734478
Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research May, 2004 | Pubmed ID: 15161698
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul, 2004 | Pubmed ID: 15173215
Neutral endopeptidase protein expression and prognosis in localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Jun, 2004 | Pubmed ID: 15217945
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Cancer Oct, 2004 | Pubmed ID: 15378501
Retinoid receptor mRNA expression profiles in human bladder cancer specimens.
International journal of oncology Apr, 2005 | Pubmed ID: 15754000
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Apr, 2005 | Pubmed ID: 15809486
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul, 2005 | Pubmed ID: 15837970
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Clinical cancer research : an official journal of the American Association for Cancer Research May, 2005 | Pubmed ID: 15867260
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine May, 2005 | Pubmed ID: 15872360
Involvement of neutral endopeptidase in neoplastic progression.
Biochimica et biophysica acta Aug, 2005 | Pubmed ID: 16054017
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2005 | Pubmed ID: 16203821
Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.
Carcinogenesis Mar, 2006 | Pubmed ID: 16344273
Antibody-based therapeutics: focus on prostate cancer.
Cancer metastasis reviews Dec, 2005 | Pubmed ID: 16408160
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
Clinical genitourinary cancer Mar, 2006 | Pubmed ID: 16729907
Chemotherapy for non-clear-cell renal cell carcinoma.
Clinical genitourinary cancer Mar, 2006 | Pubmed ID: 16729909
Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2.
The Journal of biological chemistry Nov, 2006 | Pubmed ID: 16940054
Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter.
Molecular and cellular endocrinology Oct, 2006 | Pubmed ID: 16949732
Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma.
The Journal of urology Oct, 2006 | Pubmed ID: 16952705
Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway.
The Journal of urology Oct, 2006 | Pubmed ID: 16952706
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
Cancer Dec, 2006 | Pubmed ID: 17083125
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.
Journal of translational medicine , 2007 | Pubmed ID: 17207277
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Feb, 2007 | Pubmed ID: 17290063
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jun, 2007 | Pubmed ID: 17538166
Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells.
Biochimica et biophysica acta Jul, 2007 | Pubmed ID: 17540466
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
The Journal of urology Aug, 2007 | Pubmed ID: 17561135
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) Sep, 2007 | Pubmed ID: 17667529
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.
International journal of oncology Nov, 2007 | Pubmed ID: 17912448
Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.
The Prostate Jun, 2008 | Pubmed ID: 18361411
Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.
Molecular carcinogenesis Feb, 2009 | Pubmed ID: 18623111
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
Clinical genitourinary cancer Sep, 2008 | Pubmed ID: 18824434
Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.
Cancer Apr, 2009 | Pubmed ID: 19215030
Rational redesign of neutral endopeptidase binding to merlin and moesin proteins.
Protein science : a publication of the Protein Society May, 2009 | Pubmed ID: 19388049
Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model.
Biochemical pharmacology Nov, 2009 | Pubmed ID: 19549509
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep, 2009 | Pubmed ID: 19636012
Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations.
The Journal of neuroscience : the official journal of the Society for Neuroscience Aug, 2009 | Pubmed ID: 19657023
Neutral endopeptidase is a myristoylated protein.
Molecular and cellular biochemistry Feb, 2010 | Pubmed ID: 19756956
Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature.
Journal of medical case reports , 2009 | Pubmed ID: 19918289
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.
Lab on a chip Jan, 2010 | Pubmed ID: 20024046
Is methylation the key to CD10 loss?
Journal of pediatric hematology/oncology Jan, 2010 | Pubmed ID: 20051779
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.
Cancer Feb, 2010 | Pubmed ID: 20127956
Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.
Cancer biology & therapy May, 2010 | Pubmed ID: 20200483
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.
Urologic oncology Nov-Dec, 2011 | Pubmed ID: 20451413
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
American journal of clinical oncology Oct, 2011 | Pubmed ID: 20881475
Recent advances in management of renal cancer.
F1000 medicine reports , 2009 | Pubmed ID: 20948687
Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007).
The Journal of urology May, 2011 | Pubmed ID: 21419456
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Cancer research Sep, 2011 | Pubmed ID: 21799031
Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.
Cancer research Nov, 2011 | Pubmed ID: 21908555
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.
European urology Mar, 2012 | Pubmed ID: 22099611
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Cancer discovery Nov, 2011 | Pubmed ID: 22389870
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.
PloS one , 2012 | Pubmed ID: 22558290
Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
International journal of oncology Oct, 2012 | Pubmed ID: 22895534
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
European urology May, 2013 | Pubmed ID: 22981675
Androgen receptor on the move: boarding the microtubule expressway to the nucleus.
Cancer research Sep, 2012 | Pubmed ID: 22987486
Isolation and characterization of circulating tumor cells in prostate cancer.
Frontiers in oncology , 2012 | Pubmed ID: 23087897
Negative regulation of NEP expression by hypoxia.
The Prostate May, 2013 | Pubmed ID: 23138928
Challenges in recognizing treatment-related neuroendocrine prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec, 2012 | Pubmed ID: 23169519
2-weekly versus 3-weekly docetaxel for prostate cancer.
The lancet oncology Feb, 2013 | Pubmed ID: 23294852
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
Neoplasia (New York, N.Y.) Jan, 2013 | Pubmed ID: 23358695
Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.
Cancer research May, 2013 | Pubmed ID: 23447580
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2013 | Pubmed ID: 23714732
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.
Frontiers in oncology , 2013 | Pubmed ID: 23986881
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Cancer Mar, 2014 | Pubmed ID: 24249435
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.
PloS one , 2013 | Pubmed ID: 24386459
Androgen receptor splice variants determine taxane sensitivity in prostate cancer.
Cancer research Apr, 2014 | Pubmed ID: 24556717
Immunologics and Chemotherapeutics for Renal Cell Carcinoma.
Seminars in interventional radiology Mar, 2014 | Pubmed ID: 24596445
Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential.
Molecular diagnosis & therapy May, 2014 | Pubmed ID: 24809501
Copyright © 2024 MyJoVE Corporation. Alle Rechte vorbehalten